

Alvin H. Schmaier, M.D.

Case Western Reserve University
University Hospital Case Medical Center

Bibliography:

Anticoagulant Use and Cautions:

Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. *N. Engl J Med.* 368:2113-2124, 2013

Heparin and Warfarin:

Holbrook A. *et al.* Evidence-based management of anticoagulant therapy. *Chest* 141(2)(Suppl):e152S-e184S, 2012.

Guyatt GH *et al.* Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141(2)(Suppl):7S-47S, 2012.

SAVE-ONCO Study Group. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. *N. Engl J. Med.* 366:601-9, 2012.

Target-Specific Oral Anticoagulants:

Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs. *Chest* 141(2)(Suppl):e120S-e151S, 2012.

Agno W *et al.* Oral anticoagulant therapy. *Chest* 141(2)(Suppl):e44S-e88s, 2012.

The Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. *N.Engl J. Med.* 363:2499-510, 2010.

Castellucci LA *et al.* Clinical and safety outcomes associated with treatment of acute venous thromboembolism. A systematic Review and Meta-analysis. *JAMA.* 2014;312:1122-1135.

Van Es N *et al.* Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. *Blood.* 2014;124:1968-1975.

Parenteral Anticoagulants:

Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants. *Chest* 141(2)(Suppl):e24S-e43S, 2012.

Antiplatelet Agents:

Wallentin L *et al.* Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N. Engl J Med.* 361:1045-7, 2009.

CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). *The Lancet.* 348:1329-1339, 1996.

Wiviott SD *et al.* Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N. Engl J Med.* 357:2001-15, 2007.

Becattini C *et al.* Aspirin for preventing the recurrence of venous thromboembolism. *N Engl. J. Med.* 366:1959-67, 2012.

White HD *et al.* Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. *J Am Heart Assoc.* 2014 Jul 10; 3(4).pii: 3001032. Doi: 10.1161

Held C *et al.* Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. *Eur Heart J Acute Cardiovasc Care.* Sep;3(3):246-56, 2014.

Correction of Bleeding: Warfarin, Fondaparinux, Dabigatran, Rivaroxaban, Apixaban, Endoxaban

Boulis NM *et al.* Use of factor IX complex in warfarin-related intracranial hemorrhage. *Neurosurgery.* 45:1113-1118, 1999.

Lisman T *et al.* Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. *J Thromb Haemost.* 1:2368-2373, 2003.

Eerenberg ES *et al.* Reversal of Rivaroxaban and Dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. *Circulation.* 124(14):1573-9, 2011.

Sarode R *et al.* Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. *Circulation.* 128:1234-43, 2013.

Crowther M, Crowther MA. Antidotes for novel oral anticoagulants. Current status and future potential. *Arthioscler Thromb Vasc Biol.* 2015;35:1736-1745.

Zahir H *et al.* Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. *Circ.* 2015;131:82-90.